| PubChem Standard Value | Standard Type | Standard Relation | Standard Value | Standard Units | Data Validity Comment |
|---|---|---|---|---|---|
| Percent Effect | = | -0.4113 | % | ||
| Percent Effect | = | 5.918 | % | ||
| Percent Effect | = | 24.74 | % | ||
| Percent Effect | = | -17.79 | % | ||
| Percent Effect | = | 76.74 | % | ||
| 22.7813 | IC50 | = | 22781.31 | nM | |
| Percent Effect | = | -1.838 | % | ||
| Percent Effect | = | 13.25 | % | ||
| Percent Effect | = | 8.892 | % | ||
| Percent Effect | = | -2.138 | % | ||
| Percent Effect | = | -11.1 | % | ||
| Percent Effect | = | 12.13 | % | ||
| Percent Effect | = | 5.305 | % | ||
| Percent Effect | = | 4.955 | % | ||
| Percent Effect | = | 21.13 | % | ||
| Percent Effect | = | 2.237 | % | ||
| Percent Effect | = | 8.675 | % | ||
| Percent Effect | = | -6.461 | % | ||
| Percent Effect | = | -6.594 | % | ||
| Percent Effect | = | -15.11 | % |
| PubChem Standard Value | Standard Type | Standard Relation | Standard Value | Standard Units | Data Validity Comment |
|---|---|---|---|---|---|
| Percent Effect | = | -3.24 | % | ||
| Percent Effect | = | -13.31 | % | ||
| Percent Effect | = | -14.92 | % | ||
| Percent Effect | = | 19.22 | % | ||
| Percent Effect | = | 0.5922 | % | ||
| Percent Effect | = | 5.491 | % | ||
| Percent Effect | = | 16.44 | % | ||
| Percent Effect | = | -8.493 | % | ||
| Percent Effect | = | 31.52 | % | ||
| Percent Effect | = | -34.04 | % | ||
| Percent Effect | = | 15.71 | % | ||
| Percent Effect | = | 7.437 | % | ||
| Percent Effect | = | 1.274 | % | ||
| Percent Effect | = | 47.08 | % | ||
| Percent Effect | = | -6.198 | % | ||
| Percent Effect | = | 34.07 | % | ||
| Percent Effect | = | 24.8 | % | ||
| Percent Effect | = | 26.03 | % | ||
| Percent Effect | = | -7.513 | % | ||
| Percent Effect | = | 20.66 | % |
| PubChem Standard Value | Standard Type | Standard Relation | Standard Value | Standard Units | Activity Comment | Data Validity Comment |
|---|---|---|---|---|---|---|
| 10 | MIC | > | 10000 | nM | Median N= 2; Maxinhib 10.4 Pct | |
| 20 | MIC | > | 20000 | nM | Median N= 2; Maxinhib 10.3 Pct | |
| 5 | MIC | = | 5000 | nM | Median N= 2 | |
| Inhibition | = | 22.02 | % | Average; N=2 | ||
| 10 | MIC | > | 10000 | nM | Median N= 2; Maxinhib 7.2 Pct | |
| Inhibition | = | 0.29 | % | Average; N=2 | ||
| Inhibition | = | 13.44 | % | Average; N=2 | ||
| Inhibition | = | 15.75 | % | Average; N=2 | ||
| Inhibition | = | 30.31 | % | Average; N=2 | ||
| 20 | MIC | > | 20000 | nM | Median N= 2; Maxinhib 19.9 Pct | |
| 10 | MIC | > | 10000 | nM | Median N= 2; Maxinhib 13.5 Pct | |
| Inhibition | = | 12.68 | % | Average; N=2 | ||
| Inhibition | = | 8.04 | % | Average; N=2 | ||
| Inhibition | = | 21.28 | % | Average; N=2 | ||
| 20 | MIC | > | 20000 | nM | Median N= 2; Maxinhib 17.6 Pct | |
| 10 | MIC | > | 10000 | nM | Median N= 2; Maxinhib 10.9 Pct | |
| 20 | MIC | > | 20000 | nM | Median N= 2; Maxinhib 24.8 Pct | |
| Inhibition | = | 19.94 | % | Average; N=2 | ||
| 10 | MIC | > | 10000 | nM | Median N= 2; Maxinhib 15.2 Pct | |
| Inhibition | = | 19.7 | % | Average; N=2 |
| PubChem Standard Value | Standard Type | Standard Relation | Standard Value | Standard Units | Activity Comment | Data Validity Comment |
|---|---|---|---|---|---|---|
| Inhibition | = | 10.84 | % | Average; N=1 | ||
| Inhibition | = | 14.55 | % | Average; N=1 | ||
| Inhibition | = | -13.46 | % | Average; N=1 | Outside typical range | |
| Inhibition | = | 21.47 | % | Average; N=2 | ||
| Inhibition | = | 32.07 | % | Average; N=1 | ||
| Inhibition | = | 2.27 | % | Average; N=1 | ||
| Inhibition | = | -21.74 | % | Average; N=1 | Outside typical range | |
| Inhibition | = | 9.41 | % | Average; N=1 | ||
| Inhibition | = | 19.34 | % | Average; N=1 | ||
| Inhibition | = | -25.08 | % | Average; N=1 | Outside typical range | |
| Inhibition | = | 9.21 | % | Average; N=4 | ||
| Inhibition | = | 15.98 | % | Average; N=4 | ||
| Inhibition | = | 8.03 | % | Average; N=1 | ||
| Inhibition | = | -1.26 | % | Average; N=1 | ||
| Inhibition | = | 6.81 | % | Average; N=1 | ||
| Inhibition | = | -8.48 | % | Average; N=1 | ||
| Inhibition | = | 25.25 | % | Average; N=1 | ||
| Inhibition | = | 44.67 | % | Average; N=1 | ||
| Inhibition | = | 1.69 | % | Average; N=1 | ||
| Inhibition | = | 2.93 | % | Average; N=1 |
| Max_Response | Activity at 2.29 uM | Activity at 11.40 uM | Activity at 57.10 uM | Activity at 114.0 uM | Activity at 229.0 uM | Compound QC |
|---|---|---|---|---|---|---|
| -13.2744 | -14.0597 | -11.6112 | -13.2744 | QC'd by CBC | ||
| -13.2736 | -2.2436 | -1.4106 | -3.5076 | -4.2706 | -13.2736 | QC'd by ChemBridge |
| -13.2725 | -6.3492 | -3.253 | -0.0584 | -6.7999 | -13.2725 | QC'd by Enamine |
| -13.2721 | -2.684 | -6.1454 | -14.2744 | -13.2721 | -0.8973 | QC'd by InterBioScreen |
| -13.2688 | 1.9838 | 0.4889 | -13.2688 | QC'd by CBC | ||
| -13.2682 | -4.4846 | 2.9589 | -5.115 | -5.7595 | -13.2682 | QC'd by Sytravon |
| -13.2658 | -0.93 | -4.4888 | -3.7077 | -0.7595 | -13.2658 | QC'd by Scripps Research Institute Molecular Screening Center-Florida |
| -13.2621 | -10.0397 | -8.5786 | -8.5671 | -13.2621 | -10.4851 | QC'd by InterBioScreen |
| -13.2619 | -4.902 | -18.7355 | -13.2619 | QC'd by CBC | ||
| -13.2616 | -5.6993 | -9.4488 | -8.2485 | -1.1117 | -13.2616 | QC'd by Asinex Ltd. |
| -13.2589 | -2.6923 | -5.6679 | -1.3754 | -4.9233 | -13.2589 | QC'd by ChemBridge |
| -13.2586 | -7.6996 | -6.7417 | -9.0608 | -13.2586 | 13.0861 | QC'd by Chem Div |
| -13.258 | 4.5885 | -10.8854 | -13.258 | QC'd by CBC | ||
| -13.2566 | -1.7741 | -2.7236 | -3.5771 | -3.8709 | -13.2566 | QC'd by Chem Div |
| -13.255 | -2.106 | 1.9951 | -5.3796 | -7.5294 | -13.255 | QC'd by Sytravon |
| -13.2542 | -3.8713 | -0.3776 | -5.8085 | -5.7762 | -13.2542 | QC'd by Sytravon |
| -13.2537 | -9.0401 | -8.2673 | -9.7055 | -13.2537 | QC'd by ChemBridge | |
| -13.2524 | -8.3625 | -5.9151 | -4.3599 | -2.4204 | -13.2524 | QC'd by Life Chemicals |
| -13.2524 | -11.5667 | -8.9808 | -13.1831 | -13.2524 | -13.0056 | QC'd by Enamine |
| -13.2524 | 12.6035 | 6.6367 | -13.2524 | QC'd by CBC |
| Phenotype | Potency | Efficacy | Activity_Score | Curve_Description | Fit_LogAC50 | Fit_HillSlope | Fit_R2 | Fit_InfiniteActivity | Fit_ZeroActivity | Fit_CurveClass | Excluded_Points | Max_Response | Activity at 0.00460 uM | Activity at 0.023 uM | Activity at 0.046 uM | Activity at 0.112 uM | Activity at 0.230 uM | Activity at 0.460 uM | Activity at 0.871 uM | Activity at 0.984 uM | Activity at 1.439 uM | Activity at 2.300 uM | Activity at 4.560 uM | Activity at 5.230 uM | Activity at 7.193 uM | Activity at 11.50 uM | Activity at 22.87 uM | Activity at 26.96 uM | Activity at 44.22 uM | Activity at 57.50 uM | Activity at 114.7 uM | Activity at 121.0 uM | Compound QC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Inactive | 0 | -6.8 | 4.9549 | 0.8159 | 2 | -8.876 | 4 | 0 0 0 0 | -0.3922 | -6.98 | 4.9207 | 1.8774 | -0.3922 | QC'd by CBC | |||||||||||||||||||
| Inactive | 0 | -6 | 4.9549 | 0.9989 | 3 | -8.4743 | 4 | 0 0 0 1 | -8.9436 | -8.7286 | -0.7486 | 3.1076 | -8.9436 | QC'd by CBC | |||||||||||||||||||
| Inactive | 0 | -5.45 | 1.7529 | 0.9999 | 31.5 | -1.4018 | 4 | 0 0 0 1 | 0 | -1.1682 | 2.486 | 27.8307 | 0 | QC'd by CBC | |||||||||||||||||||
| Inactive | 0 | -6 | 0.6 | 0.9574 | -3.5578 | 18 | 4 | 0 0 0 0 | -2.9648 | 13.9674 | 5.3752 | 2.1822 | -2.9648 | QC'd by CBC | |||||||||||||||||||
| Activator | 0.8913 | 55.3545 | 0 | Complete curve; partial efficacy; poor fit | -6.05 | 4.9549 | 0.9968 | 47.9876 | -7.3669 | 1.4 | 0 0 0 0 | 45.9161 | -7.5163 | 36.2451 | 49.4307 | 45.9161 | QC'd by CBC | ||||||||||||||||
| Inactive | 0 | 4 | -0.4061 | 3.1581 | 7.1489 | 1.8466 | -0.4061 | QC'd by CBC | |||||||||||||||||||||||||
| Inactive | 0 | 4 | 8.0219 | 9.7586 | 2.6391 | 4.515 | 8.0219 | QC'd by CBC | |||||||||||||||||||||||||
| Inactive | 0 | -4.7 | 2.9023 | 0.9336 | 14 | -3.7678 | 4 | 0 0 0 0 | 13.2222 | -6.4732 | -1.1472 | -0.6942 | 13.2222 | QC'd by CBC | |||||||||||||||||||
| Inactive | 0 | -6.75 | 4.9549 | 0.6234 | 5.5 | -2.8563 | 4 | 0 0 0 1 | -0.8656 | -1.9636 | 9.114 | 2.2001 | -0.8656 | QC'd by CBC | |||||||||||||||||||
| Activator | 3.1623 | 120.5805 | 0 | Partial curve; high efficacy; poor fit | -5.5 | 2.5884 | 1 | 125.8416 | 5.2611 | 2.3 | 0 0 0 1 | -13.8758 | 5.0261 | 13.541 | 121.9395 | -13.8758 | QC'd by CBC | ||||||||||||||||
| Inactive | 0 | -5.05 | 4.095 | 0.995 | 39.9163 | 10.5 | 4 | 0 0 0 0 | 39.907 | 11.8101 | 9.2103 | 32.1484 | 39.907 | QC'd by CBC | |||||||||||||||||||
| Inactive | 0 | -6.75 | 4.9549 | 0.6885 | 5.5 | -14.2723 | 4 | 0 0 0 0 | -1.4364 | -12.3103 | 13.1505 | 4.6329 | -1.4364 | QC'd by CBC | |||||||||||||||||||
| Inactive | 0 | -6.8 | 4.9549 | 0.4877 | 7 | -4.299 | 4 | 0 0 0 0 | 12.0135 | -2.3325 | 8.0236 | 0.5611 | 12.0135 | QC'd by CBC | |||||||||||||||||||
| Activator | 14.1254 | 56.9966 | 0 | Partial curve; partial efficacy; poor fit | -4.85 | 1.5579 | 0.9975 | 55.2294 | -1.7671 | 2.4 | 0 0 0 0 | 49.6994 | -2.5363 | 1.1452 | 21.5084 | 49.6994 | QC'd by CBC | ||||||||||||||||
| Inactive | 0 | -6.7 | 4.9549 | 0.6978 | 8.5 | -0.5 | 4 | 0 0 0 1 | 0.9512 | 0.1013 | 11.4064 | 5.1489 | 0.9512 | QC'd by CBC | |||||||||||||||||||
| Inactive | 0 | -6.8 | 4.9549 | 0.671 | 13 | -7.7542 | 4 | 0 0 0 1 | 0 | -4.3785 | 20.2445 | 6.0485 | 0 | QC'd by CBC | |||||||||||||||||||
| Inactive | 0 | 4 | -3.0754 | -7.5861 | -4.61 | -0.5732 | -3.0754 | QC'd by CBC | |||||||||||||||||||||||||
| Inactive | 0 | -4.95 | 0.7 | 0.969 | -2 | 20.5 | 4 | 0 0 0 0 | 2.437 | 20.2378 | 15.4328 | 10.7009 | 2.437 | QC'd by CBC | |||||||||||||||||||
| Inactive | 0 | -6.8 | 4.5045 | 0.7622 | -2 | -15.313 | 4 | 0 0 0 0 | -4.8971 | -12.7608 | 2.2051 | -3.2116 | -4.8971 | QC'd by CBC | |||||||||||||||||||
| Inactive | 0 | -6.05 | 4.5045 | 0.9997 | 13 | -6.5465 | 4 | 0 0 0 1 | 0 | -6.2888 | 8.2825 | 12.9406 | 0 | QC'd by CBC |
| Activity at 15 uM | Phenotype |
|---|---|
| -3.1 | |
| 4.2 | |
| -4.8 | |
| -0.6 | |
| -3.9 | |
| -6 | |
| 75.3 | Inhibitor |
| -10.3 | |
| -7 | |
| -2 | |
| -3.8 | |
| 17.6 | |
| -4.8 | |
| -4.1 | |
| -7.8 | |
| -7.5 | |
| 15.2 | |
| 7.8 | |
| -2.5 | |
| -13.4 |
| Phenotype | Potency | Efficacy | Activity_Score | Curve_Description | Fit_LogAC50 | Fit_HillSlope | Fit_R2 | Fit_InfiniteActivity | Fit_ZeroActivity | Fit_CurveClass | Excluded_Points | Max_Response | Activity at 0.00460 uM | Activity at 0.023 uM | Activity at 0.046 uM | Activity at 0.092 uM | Activity at 0.115 uM | Activity at 0.230 uM | Activity at 0.460 uM | Activity at 0.911 uM | Activity at 1.057 uM | Activity at 1.771 uM | Activity at 2.301 uM | Activity at 4.634 uM | Activity at 5.773 uM | Activity at 11.50 uM | Activity at 16.40 uM | Activity at 23.82 uM | Activity at 35.99 uM | Activity at 57.50 uM | Activity at 114.4 uM | Activity at 129.1 uM | Activity at 273.4 uM | Activity at 288.0 uM | Compound QC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Activator | 15.8489 | 72.7667 | 0 | Partial curve; partial efficacy; poor fit | -4.8 | 1 | 0.9956 | 71.5604 | -1.2063 | 2.4 | 0 0 0 0 | 56.9219 | -2.7032 | 5.7184 | 29.0721 | 56.9219 | QC'd by CBC | ||||||||||||||||||
| Inactive | 0 | -5.65 | 2.7202 | 0.876 | -3.076 | -11.1378 | 4 | 0 0 0 0 | -4.8556 | -10.9482 | -10.07 | -0.8967 | -4.8556 | QC'd by CBC | |||||||||||||||||||||
| Activator | 14.1254 | 116.3598 | 0 | Partial curve; high efficacy; poor fit | -4.85 | 2.2526 | 0.9976 | 114.9836 | -1.3761 | 2.3 | 0 0 0 0 | 110.7742 | -4.0165 | 2.5263 | 42.9951 | 110.7742 | QC'd by CBC | ||||||||||||||||||
| Inactive | 0 | -4.35 | 4.9549 | 0.6203 | 9 | -2.1257 | 4 | 0 0 0 0 | 6.649 | -3.8222 | 2.8199 | -4.6881 | 6.649 | QC'd by CBC | |||||||||||||||||||||
| Activator | 22.3872 | 69.8021 | 0 | Partial curve; partial efficacy | -4.65 | 1.7529 | 0.999 | 66.6142 | -3.1879 | 2.2 | 0 0 0 0 | 55.5041 | -3.9302 | -1.5453 | 13.5134 | 55.5041 | QC'd by CBC | ||||||||||||||||||
| Inactive | 0 | 4 | -10.8628 | -6.0946 | -6.3923 | -2.7723 | -10.8628 | QC'd by CBC | |||||||||||||||||||||||||||
| Activator | 3.1623 | 46.5616 | 0 | Complete curve; partial efficacy | -5.5 | 1 | 1 | 40.0835 | -6.4781 | 1.2 | 0 0 0 0 | 37.587 | -4.7841 | 6.0554 | 30.2065 | 37.587 | QC'd by CBC | ||||||||||||||||||
| Inactive | 0 | 4 | -5.1322 | -4.7917 | -1.3649 | -10.6528 | -5.1322 | QC'd by CBC | |||||||||||||||||||||||||||
| Inactive | 0 | -4.4 | 4.4495 | 0.7339 | 13 | 0.9992 | 4 | 0 0 0 0 | 11.2209 | -2.5007 | 5.0259 | 0.3015 | 11.2209 | QC'd by CBC | |||||||||||||||||||||
| Inactive | 0 | 4 | 11.7523 | 6.5427 | 3.7075 | 3.7602 | 11.7523 | QC'd by CBC | |||||||||||||||||||||||||||
| Inactive | 0 | 4 | -13.953 | -10.1902 | -10 | -18.4577 | -13.953 | QC'd by CBC | |||||||||||||||||||||||||||
| Inactive | 0 | 4 | -4.5083 | -2.0629 | 5.4547 | -1.4612 | -4.5083 | QC'd by CBC | |||||||||||||||||||||||||||
| Inactive | 0 | 4 | -7.5306 | -15.4441 | -6.4413 | -15.0974 | -7.5306 | QC'd by CBC | |||||||||||||||||||||||||||
| Inactive | 0 | -4.65 | 2.2526 | 0.9477 | -26.3385 | -15.8934 | 4 | 0 0 0 0 | -25.2821 | -17.3753 | -14.9112 | -17.8522 | -25.2821 | QC'd by CBC | |||||||||||||||||||||
| Inactive | 0 | 4 | -12.6647 | -11.4457 | -10.7961 | -20.5075 | -12.6647 | QC'd by CBC | |||||||||||||||||||||||||||
| Inactive | 0 | -5.1 | 4.9549 | 0.594 | -16.1597 | -5.6067 | 4 | 0 0 0 1 | -3.9011 | -10.3012 | -3.0056 | -14.7164 | -3.9011 | QC'd by CBC | |||||||||||||||||||||
| Inactive | 0 | -5.15 | 4.9549 | 0.9234 | -15.5602 | -3.9488 | 4 | 0 0 0 1 | -5.8836 | -5.9172 | -2.4573 | -14.6335 | -5.8836 | QC'd by CBC | |||||||||||||||||||||
| Inactive | 0 | -4.35 | 4.4495 | 0.7251 | -13.3612 | -2 | 4 | 0 0 0 0 | -10.7177 | -1.1966 | -5.5978 | 0.8791 | -10.7177 | QC'd by CBC | |||||||||||||||||||||
| Inactive | 0 | -5.7 | 4.5045 | 0.8075 | 1.0108 | 10.5 | 4 | 0 0 0 0 | 4.4351 | 10.6905 | 9.7726 | -1.6577 | 4.4351 | QC'd by CBC | |||||||||||||||||||||
| Activator | 35.4813 | 30.7807 | 0 | Partial curve; partial efficacy; poor fit | -4.45 | 1.4781 | 0.9703 | 47.2807 | 16.5 | 2.4 | 0 0 0 0 | 37.2969 | 14.4206 | 18.8162 | 21.2663 | 37.2969 | QC'd by CBC |
| PubChem Standard Value | Standard Type | Standard Relation | Standard Value | Standard Units | Activity Comment | Data Validity Comment |
|---|---|---|---|---|---|---|
| Inhibition | = | -33.42 | % | Average; N=1 | Outside typical range | |
| Inhibition | = | 1.44 | % | Average; N=1 | ||
| Inhibition | = | -11.05 | % | Average; N=1 | Outside typical range | |
| Inhibition | = | 19.22 | % | Average; N=1 | ||
| Inhibition | = | -31.54 | % | Average; N=1 | Outside typical range | |
| Inhibition | = | -12.91 | % | Average; N=1 | Outside typical range | |
| Inhibition | = | 12.18 | % | Average; N=1 | ||
| Inhibition | = | -14.83 | % | Average; N=1 | Outside typical range | |
| Inhibition | = | 17.54 | % | Average; N=1 | ||
| Inhibition | = | -38.58 | % | Average; N=1 | Outside typical range | |
| Inhibition | = | -10.22 | % | Average; N=1 | Outside typical range | |
| Inhibition | = | 14 | % | Average; N=1 | ||
| Inhibition | = | 1.67 | % | Average; N=1 | ||
| Inhibition | = | 14.76 | % | Average; N=1 | ||
| Inhibition | = | -28.2 | % | Average; N=1 | Outside typical range | |
| Inhibition | = | 13.08 | % | Average; N=1 | ||
| Inhibition | = | 3.75 | % | Average; N=1 | ||
| Inhibition | = | 10.88 | % | Average; N=1 | ||
| Inhibition | = | -0.78 | % | Average; N=1 | ||
| Inhibition | = | -7.12 | % | Average; N=1 |
| Species | Strain | IsPseudotypeVirus | AssayMeth | CellType | CellType2 | Target | Mutations | EC50Mod | EC50 | EC50Unit | ECOtherPct | ECOtherPctUnit | ECOtherConc | ECOtherConcUnit | ToxAssayMeth | ToxCellType | CC50Mod | CC50 | CC50Unit | TIMod | TI | RelResFoldChg | Comments | Reference | Citation | Other Information |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HIV-1 | LAI | RT | HuT TK+ | HuT 78 | Reverse transcriptase | < | 1 | uM | 100 | % | 1 | uM | MTT | > | 10 | uM | > | 10 | HuT TK+=HuT 78 CELLS EXPRESSING HSV-1 THYMIDINE KINASE; MEASUREMENT WAS MADE ON DAY10 POSTINFECTION AT 10 TCID50 | 9281520 | USE OF HERPES SIMPLEX VIRUS THYMIDINE KINASE TO IMPROVE THE ANTIVIRAL ACTIVITY OF ZIDOVUDINE. Virology 1997, 235, 398-405. | |||||
| HIV-1 | MN | RT | HuT TK+ | HuT 78 | Reverse transcriptase | < | 0.3 | uM | 76.74 | % | 0.3 | uM | MTT | > | 10 | uM | > | 33.3 | HuT TK+=HuT 78 CELLS EXPRESSING HSV-1 THYMIDINE KINASE; MEASUREMENT WAS MADE ON DAY14 POSTINFECTION AT 10 TCID50 | 9281520 | USE OF HERPES SIMPLEX VIRUS THYMIDINE KINASE TO IMPROVE THE ANTIVIRAL ACTIVITY OF ZIDOVUDINE. Virology 1997, 235, 398-405. | |||||
| HIV-1 | MN | RT | HuT TK+ | HuT 78 | Reverse transcriptase | < | 0.3 | uM | 69 | % | 0.3 | uM | MTT | > | 10 | uM | > | 33.3 | HuT TK+=HuT 78 CELLS EXPRESSING HSV-1 THYMIDINE KINASE; MEASUREMENT WAS MADE ON DAY14 POSTINFECTION AT 100 TCID50 | 9281520 | USE OF HERPES SIMPLEX VIRUS THYMIDINE KINASE TO IMPROVE THE ANTIVIRAL ACTIVITY OF ZIDOVUDINE. Virology 1997, 235, 398-405. | |||||
| R5; CLINICAL ISOLATE | 1(JSL) | P24 | PBMC | Reverse transcriptase | MDR | 0.07 | uM | 90 | % | 1 | uM | MTT | > | 100 | uM | > | 1428 | HIV-1(JSL) WAS ISOLATED FROM PATIENTS WHO RECEIVED ANTIRETROVIRAL THERAPY FOR A LONG PERIOD AND WHOSE VIRUS ACQUIRED A NUMBER OF MUTATIONS IN THE RT- AND PR-ENCODING GENES; DETAILS OF MUTATIONS NOT GIVEN | 15280474 | SPIRODIKETOPIPERAZINE-BASED CCR5 INHIBITOR WHICH PRESERVES CC-CHEMOKINE/CCR5 INTERACTIONS AND EXERTS POTENT ACTIVITY AGAINST R5 HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 IN VITRO. Journal of Virology 2004, 78(16), 8654-8662. | ECOtherConcMod:> | |||||
| HIV-1 | NL4-3 | LUCIFERASE | 1G5 T | Reverse transcriptase | < | 1 | uM | 99 | % | 1 | uM | TRYPAN BLUE | > | 1 | uM | > | 1 | ASSAY WAS CONDUCTED ON DAY 3 POST-INFECTION | 16725040 | INHIBITION OF HIGHLY PRODUCTIVE HIV-1 INFECTION IN T CELLS, PRIMARY HUMAN MACROPHAGES, MICROGLIA, AND ASTROCYTES BY SARGASSUM FUSIFORME. AIDS Research and Therapy 2006, 3(1), 15 PP. | CCOtherPct:6 | CCOtherPctUnit:% | CCOtherConc:1 | CCOtherConcUnit:uM | |||||
| HIV-1 | NL4-3 | LUCIFERASE | 1G5 T | Reverse transcriptase | < | 1 | uM | 99 | % | 1 | uM | TRYPAN BLUE | > | 1 | uM | > | 1 | ASSAY WAS CONDUCTED ON DAY 5 POST-INFECTION | 16725040 | INHIBITION OF HIGHLY PRODUCTIVE HIV-1 INFECTION IN T CELLS, PRIMARY HUMAN MACROPHAGES, MICROGLIA, AND ASTROCYTES BY SARGASSUM FUSIFORME. AIDS Research and Therapy 2006, 3(1), 15 PP. | CCOtherPct:7 | CCOtherPctUnit:% | CCOtherConc:1 | CCOtherConcUnit:uM | |||||
| HIV-1 | NL4-3 | LUCIFERASE | 1G5 T | Reverse transcriptase | < | 1 | uM | 99 | % | 1 | uM | TRYPAN BLUE | > | 1 | uM | > | 1 | ASSAY WAS CONDUCTED ON DAY 7 POST-INFECTION | 16725040 | INHIBITION OF HIGHLY PRODUCTIVE HIV-1 INFECTION IN T CELLS, PRIMARY HUMAN MACROPHAGES, MICROGLIA, AND ASTROCYTES BY SARGASSUM FUSIFORME. AIDS Research and Therapy 2006, 3(1), 15 PP. | CCOtherPct:3 | CCOtherPctUnit:% | CCOtherConc:1 | CCOtherConcUnit:uM | |||||
| HIV-1 | LAV | RT | U1(THF-.alpha. STIM) | U1 | Tumor necrosis factor alpha | ~ | 30 | ug/mL | 70 | % | 50 | ug/mL | > | 50 | ug/mL | > | 1.66 | CHRONICALLY HIV-1 INFECTED PROMONOCYTE CELL LINE | 8327469 | THALIDOMIDE INHIBITS THE REPLICATION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1. Proceedings of the National Academy of Sciences of the United States of America 1993, 90, 5974-5978. | CCOtherPct:0 | CCOtherPctUnit:% | CCOtherConc:50 | CCOtherConcUnit:ug/mL | |||||
| HIV-1 | BaL | P24 (DAY 18) | MACROPHAGES(GM-CSF) | Macrophage | Ribonucleotide reductase | < | 10 | uM | 75 | % | 10 | uM | > | 1000 | uM | > | 10 | MAXIMAL P24 EXPRESSION AT DAY 18 | 7973634 | HYDROXYUREA AS AN INHIBITOR OF HUMAN IMMUNODEFICIENCY VIRUS-TYPE 1 REPLICATION. Science 1994, 266(5186), 801-805. | CCOtherPct:0 | CCOtherPctUnit:% | CCOtherConc:1000 | CCOtherConcUnit:uM | |||||
| HIV-1 | BaL | P24 (DAY 18) | MACROPHAGES(GM-CSF) | Macrophage | Ribonucleotide reductase | < | 10 | uM | 38 | % | 2 | uM | > | 1000 | uM | > | 10 | MAXIMAL P24 EXPRESSION AT DAY 18 | 7973634 | HYDROXYUREA AS AN INHIBITOR OF HUMAN IMMUNODEFICIENCY VIRUS-TYPE 1 REPLICATION. Science 1994, 266(5186), 801-805. | CCOtherPct:0 | CCOtherPctUnit:% | CCOtherConc:1000 | CCOtherConcUnit:uM | |||||
| HIV-1 | BaL | P24 (DAY 18) | MACROPHAGES(GM-CSF) | Macrophage | Ribonucleotide reductase | < | 10 | uM | 99 | % | 50 | uM | > | 1000 | uM | > | 10 | MAXIMAL P24 EXPRESSION AT DAY 18 | 7973634 | HYDROXYUREA AS AN INHIBITOR OF HUMAN IMMUNODEFICIENCY VIRUS-TYPE 1 REPLICATION. Science 1994, 266(5186), 801-805. | ECOtherPctMod:> | CCOtherPct:0 | CCOtherPctUnit:% | CCOtherConc:1000 | CCOtherConcUnit:uM | |||||
| HIV-1 | IIIB | RT | HT4(R116; AZT RESISTANT CELLS) | HT4 | Reverse transcriptase | ~ | 0.01 | uM | 70 | % | 0.01 | uM | ~` | 1 | uM | ~ | 100 | FLOXURIDINE APPEARS TO POTENTIATE AZT ACTIVITY AND ALSO HAVE SOME ANTI-HIV ACTIVITY IN AZT RESISTANT CELL LINES | 8827211 | USE OF FLOXURIDINE TO MODULATE THE ANTIVIRAL ACTIVITY OF ZIDOVUDINE. AIDS Research and Human Retroviruses 1996, 12(11), 965-968. | ECOtherPctMod:~ | CCOtherPct:35 | CCOtherPctUnit:% | CCOtherConc:.1 | CCOtherConcUnit:uM | |||||
| HIV-1 | 1 | .beta.GAL AS A MEASURE OF TAT-MEDIATED TRANSACTIVATION | HeLa H12(HIV-1 LTR-Laz, TAT) | HeLa | Tat:TAR/LTR | < | 0.1 | uM | 52 | % | 0.1 | uM | TRYPAN BLUE | > | 100 | uM | > | 1000 | DRUG AND RECOMBINANT TAT WERE INTRODUCED INTO CELLS THROUGH ELECTROPORATION | 9561563 | CURCUMIN AND CURCUMIN DERIVATIVES INHIBIT TAT-MEDIATED TRANSACTIVATION OF TYPE 1 HUMAN IMMUNODEFICIENCY VIRUS LONG TERMINAL REPEAT. Research in Virology 1998, 149(1), 43-52. | |||||
| HIV-1 | 1 | .beta.GAL AS A MEASURE OF TAT-MEDIATED TRANSACTIVATION | HeLa H12(HIV-1 LTR-Laz, TAT) | HeLa | Tat:TAR/LTR | < | 0.01 | uM | 78 | % | 0.01 | uM | TRYPAN BLUE | > | 100 | uM | > | 10000 | DRUG AND RECOMBINANT TAT WERE INTRODUCED INTO CELLS THROUGH ELECTROPORATION | 9561563 | CURCUMIN AND CURCUMIN DERIVATIVES INHIBIT TAT-MEDIATED TRANSACTIVATION OF TYPE 1 HUMAN IMMUNODEFICIENCY VIRUS LONG TERMINAL REPEAT. Research in Virology 1998, 149(1), 43-52. | |||||
| HIV-1 | IIIB | SYNCYT FORM | MOLT-4/H9(HIV-1(IIIB)) | MOLT-4 | gp120 | < | 1 | uM | 95 | % | 10 | uM | -100 | 10 | uM | > | 10 | CHRONICALLY INFECTED H9 CELLS | 9343823 | TRIAZINE DYES INHIBIT HIV-1 ENTRY BY BINDING TO ENVELOPE GLYCOPROTEINS. Microbiology and Immunology 1997, 41(9), 717-724. | CCOtherPct:30 | CCOtherPctUnit:% | CCOtherConc:10 | CCOtherConcUnit:uM | |||||
| HIV-1 | 1 | .beta.GAL AS A MEASURE OF TAT-MEDIATED TRANSACTIVATION | HeLa H12(HIV-1 LTR-Laz, TAT) | HeLa | Tat:TAR/LTR | < | 0.01 | uM | 75 | % | 0.01 | uM | TRYPAN BLUE | > | 100 | uM | > | 10000 | DRUG AND RECOMBINANT TAT WERE INTRODUCED INTO CELLS THROUGH ELECTROPORATION | 9561563 | CURCUMIN AND CURCUMIN DERIVATIVES INHIBIT TAT-MEDIATED TRANSACTIVATION OF TYPE 1 HUMAN IMMUNODEFICIENCY VIRUS LONG TERMINAL REPEAT. Research in Virology 1998, 149(1), 43-52. | |||||
| HIV-1 | 1 | P24 | MT-4 | Integrase | < | 0.25 | uM | 95 | % | 0.25 | uM | MICROSCOPIC EXAMINATION | > | 20 | uM | > | 80 | IN THE PRESENCE OF 50% NHS | 16554152 | A SERIES OF 5-AMINOSUBSTITUTED 4-FLUOROBENZYL-8-HYDROXY-[1,6]NAPHTHYRIDINE-7-CARBOXAMIDE HIV-1 INTEGRASE INHIBITORS. Bioorganic & Medical Chemistry Letters 2006, 16(11), 2900-2904. | ECOtherPctMod:> | |||||
| HIV-1 | 1 | P24 | MT-4 | Integrase | < | 0.103 | uM | 95 | % | 0.103 | uM | MICROSCOPIC EXAMINATION | > | 20 | uM | > | 194 | IN THE PRESENCE OF 10% FBS | 16554152 | A SERIES OF 5-AMINOSUBSTITUTED 4-FLUOROBENZYL-8-HYDROXY-[1,6]NAPHTHYRIDINE-7-CARBOXAMIDE HIV-1 INTEGRASE INHIBITORS. Bioorganic & Medical Chemistry Letters 2006, 16(11), 2900-2904. | ECOtherPctMod:> | |||||
| HIV-1 | NL4-3 | RT | MT-4 | Reverse transcriptase | < | 1 | uM | 100 | % | 1 | uM | WST-8 | > | 1 | uM | > | 1 | MEASUREMENTS WERE MADE ON DAY 4, 6 AND 8 POST INFECTION | 15371436 | POLYARGININE INHIBITS GP160 PROCESSING BY FURIN AND SUPPRESSES PRODUCTIVE HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTION. The Journal of Biological Chemistry 2004, 279(47), 49055-49063. | ||||||
| HIV-1 | LAI | RT | HuT 78 | Reverse transcriptase | < | 1 | uM | 57.14 | % | 1 | uM | MTT | > | 10 | uM | > | 10 | MEASUREMENT WAS MADE ON DAY10 POSTINFECTION AT 10 TCID50 | 9281520 | USE OF HERPES SIMPLEX VIRUS THYMIDINE KINASE TO IMPROVE THE ANTIVIRAL ACTIVITY OF ZIDOVUDINE. Virology 1997, 235, 398-405. |